MERIDIAN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in People with ALS (MDA 2023) - Apellis Medical Hub

MERIDIAN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in People with ALS

Share Via Email

Back to Conference Resources

ALS Congress Presentations MDA Clinical and Scientific Conference 2023

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.